Roivant Sciences Ltd.
http://roivant.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roivant Sciences Ltd.
Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy
Roivant’s brepocitinib bests data Humira previously posted in non-infectious uveitis, a top cause of blindness. The TYK2/JAK1 inhibitor also is in Phase III for dermatomyositis.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Roivant Shopping For Multiple, Transformative Deals
The company is looking to spend some of the cash it earned on the sale of Telavant on new assets that will join the late-stage pipeline.
Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects
After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice